United Therapeutics (NASDAQ:UTHR) Given New $701.00 Price Target at Royal Bank Of Canada

Key Points

• Royal Bank of Canada trimmed its price target on United Therapeutics to $701 (from $707) but maintained an "outperform" rating, implying roughly a 22% upside from the prior close.
• Shares fell about 3.8% to $573.98 after Q1 results missed expectations — EPS $5.82 vs. $7.00 consensus and revenue $781.5M vs. $797.4M — creating short-term pressure on the stock.
• There has been heavy insider selling (including the CFO and COO) with insiders offloading hundreds of thousands of shares over the past three months, which may weigh on sentiment despite broad analyst buy/overweight coverage and a consensus target near $619.42.

United Therapeutics (NASDAQ:UTHR - Get Free Report) had its target price dropped by analysts at Royal Bank Of Canada from $707.00 to $701.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has an "outperform" rating on the biotechnology company's stock. Royal Bank Of Canada's price target indicates a potential upside of 22.13% from the company's previous close.

Several other research analysts have also issued reports on UTHR. UBS Group upped their target price on United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a research report on Thursday, March 5th. Raymond James Financial began coverage on United Therapeutics in a report on Friday, April 10th. They issued an "outperform" rating and a $700.00 price target for the company. Cantor Fitzgerald upped their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a report on Thursday, March 12th. TD Cowen increased their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a research report on Monday, March 30th. Finally, HC Wainwright lifted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research note on Tuesday, March 31st. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $619.42.

United Therapeutics Stock Down 3.8%

Shares of NASDAQ UTHR traded down $22.78 during trading hours on Thursday, hitting $573.98. 380,429 shares of the stock were exchanged, compared to its average volume of 479,562. The company has a market cap of $24.26 billion, a PE ratio of 20.56, a PEG ratio of 1.63 and a beta of 0.60. The firm has a fifty day moving average price of $548.25 and a 200-day moving average price of $500.41. United Therapeutics has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same quarter last year, the business earned $6.63 earnings per share. United Therapeutics's revenue was down 1.6% on a year-over-year basis. As a group, equities analysts anticipate that United Therapeutics will post 27.97 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the firm's stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $9,956,712.48. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the company's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $474.65, for a total value of $10,679,625.00. The SEC filing for this sale provides additional information. Insiders sold 467,355 shares of company stock worth $255,900,484 over the last three months. Corporate insiders own 10.30% of the company's stock.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Torren Management LLC purchased a new stake in shares of United Therapeutics in the fourth quarter worth about $26,000. Activest Wealth Management boosted its position in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC grew its stake in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. increased its holdings in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics during the 4th quarter valued at approximately $31,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Investors are focusing on strong clinical readouts and pipeline potential — market commentary highlights positive Tyvaso data in IPF and ralinepag’s “blockbuster” potential, which helped sentiment despite the quarter’s misses. UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook
• Positive Sentiment: Several analysts have raised price targets and maintain buy/overweight views, supporting longer-term upside expectations and cushioning the selloff. Analyst Coverage and Price Targets on UTHR
• Neutral Sentiment: The company filed its official Q1 release and slide deck providing detail on results and ongoing trials; useful for investors but not market-moving by itself. United Therapeutics Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Expansion of a DPI partnership (reported in coverage of MannKind’s stock move) signals continued device/partnership activity that could be incremental to UTHR’s inhaled product strategy, though the immediate impact on UTHR revenue is unclear. MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership
• Negative Sentiment: United Therapeutics missed EPS and revenue estimates for Q1 (EPS $5.82 vs. consensus, revenue $781.5M below estimates), creating short-term pressure as results fell short of expectations. UTHR Misses Q1 Estimates
• Negative Sentiment: Insider selling: CEO Martine Rothblatt and CFO James Edgemond disclosed sizable sales on May 4, which can weigh on sentiment and raise questions for some investors about near-term insider conviction. Insider Sales by UTHR Executives

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.